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Cancer stem cells (CSCs) have been suggested as
potential therapeutic targets for treating malignant
tumors, but the in vivo supporting evidence is still
missing. Using aGFP reporter driven by the promoter
of the nuclear receptor tailless (Tlx), we demonstrate
that Tlx+ cells in primary brain tumors are mostly
quiescent. Lineage tracing demonstrates that single
Tlx+ cells can self-renew and generate Tlx tumor
cells in primary tumors, suggesting that they are
brain tumor stem cells (BTSCs). After introducing a
BTSC-specific knock-out of the Tlx gene in primary
mouse tumors, we observed a loss of self-renewal
of BTSCs and prolongation of animal survival,
accompanied by induction of essential signaling
pathways mediating cell-cycle arrest, cell death,
and neural differentiation. Our study demonstrates
the feasibility of targeting glioblastomas and indi-
cates the suitability of BTSCs as therapeutic targets,
thereby supporting the CSC hypothesis.
INTRODUCTION
The cancer stem cell (CSC) hypothesis provides an alternative
model to explain the tumor cell heterogeneity (Reya et al.,
2001). Like normal somatic adult stem cells, which are distrib-
uted in different tissues, CSCs are thought to be the less differ-
entiated populations in malignant tissues and are considered
to be the cells that are responsible for the maintenance of tumor
tissues, as well as for the relapse of tumors after conventional
treatment. In most tumor entities, the existence of CSCs has
not been demonstrated in vivo with the genetic cell fate mapping
approach, which is the most stringent criterion for the identifica-
tion of normal tissue stem cells (Clevers, 2011). Using lineageCtracing, a very recent study performed in a mouse colon
adenoma model showed that Lgr5-expressing cells are CSCs
(Schepers et al., 2012). This study provided the first solid
evidence for the presence of CSCs in unperturbed primary
tumors. The CSC hypothesis rises the anticipation that targeting
of CSCs in tumors will lead to an improved clinical outcome
because they are thought to be the ‘‘root’’ of growing tumors.
However, the in vivo experimental evidence supporting that is
still missing in most tumor entities.
Brain tumor stem cells (BTSC) are one of the first CSCs
identified in solid tumors (Singh et al., 2003, 2004). CD133
has been suggested to be a useful marker for isolation of
BTSCs but the results obtained based on this method are
controversial (Clevers, 2011). BTSCs share many similarities
with normal neural stem cells (NSCs), i.e., expression of
markers like Nestin and CD133, or sphere-forming ability
when placed into medium containing growth factors (Vescovi
et al., 2006). It would not be surprising if BTSCs could hijack
the self-renewal pathway of normal NSCs, and similar results
have been found in many other type of tumors (He et al.,
2009). Several studies tried to target factors that are known to
be important of NSC maintenance during brain tumorigenesis.
Inhibitor of DNA binding 1 (Id1) is selectively expressed in
NSCs in adult neurogenic niches, namely the subventricular
zone (SVZ) and the subgranular zone (SGZ) and Id proteins
are shown to be involved in regulation of stem cell self-renewal
(Nam and Benezra, 2009). However, deletion of Id1 in mouse
brain tumors has modest effects on animal survival, although
BTSCs of Id1 mutants have reduced self-renewal capacity
in vitro (Barrett et al., 2012). This leads to the assumption that
the self-renewal of BTSCs does not predict brain tumor growth
potential, however, it is noteworthy that Id1 mutant animals
have normal NSCs populations and normal neurogenesis (Bar-
rett et al., 2012). A recent study using a cell ablation approach
demonstrated that chemo-resistant Nestin expressing brain tu-
mor cells are responsible for brain tumor propagation, and abla-
tion of these cells led to prolonged survival of tumor-bearing
mice (Chen et al., 2012), which support that self-renewing tumorell Stem Cell 15, 185–198, August 7, 2014 ª2014 Elsevier Inc. 185
Figure 1. Induction of High-Grade Brain Tumors in Ntv-a Mice
(A) Hematoxylin and eosin (H&E) staining of GB induced with PDGFB and AKT in the Nestin-Tv-a model. Scale bar represents 100 mm.
(B andC) Brain tumors inducedwith PDGFB andAKT have typical pathological features like pseudopalisading and necrosis (B, N indicates the necrotic areas) and
vascular proliferation (C, arrows). Scale bar represents 50 mm.
(D and E) The mouse tumors highly express the astrocyte marker GFAP (D) and the proliferation marker Ki67 (E). Scale bar represents 20 mm.
(F) Kaplan-Meier survival curve of the Ntv-a mice induced with PDGFB and AKT (n = 15). RCAS-GFP was used as control vector (n = 12).
See also Figure S1.
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The nuclear receptor tailless (Tlx, Nr2e1) is specifically ex-
pressed in adult NSCs and loss of Tlx in mice leads to the
loss of self-renewal of NSCs, both in the SVZ and the SGZ
(Liu et al., 2008, 2010; Shi et al., 2004; Zhang et al., 2008;
Zou et al., 2012). Interestingly, Tlx is also overexpressed in hu-
man brain tumors and it is important for tumor initiation from the
SVZ (Liu et al., 2010; Zou et al., 2012). These results suggest
that Tlx is a crucial regulator for self-renewal of adult NSCs
and brain tumorigenesis. However, the expression pattern and
function of Tlx in established tumors is unknown.
To investigate whether BTSCs are important for tumor main-
tenance and survival, we generated a mouse brain tumor
model, which allows cell-type-specific genetic manipulation in
fully developed primary brain tumors. We found that the Tlx+
cells are the slow-dividing and undifferentiated tumor cells
in vivo, xenotransplantation, and lineage tracing directly demon-
strates that they are the BTSCs. An inducible inactivation of Tlx in
Nestin expressing brain tumor cells leads to a significant pro-
longation of survival of tumor-bearing animals. Tumor cells
from Tlx-deficient tumors lost self-renewing capacity and re-
sulted in less proliferating cells. In addition, we identified several
important signaling pathways involved in cell-cycle arrest, cell
death, and neural differentiation. Overall, this study demon-
strates the direct genetic evidence of the importance of CSC in
brain tumors and provides an attractive therapeutic target of
high-grade gliomas.186 Cell Stem Cell 15, 185–198, August 7, 2014 ª2014 Elsevier Inc.RESULTS
A Mouse Model for Gene Targeting in Fully Developed
High-Grade Brain Tumors
To establish a mouse model that allows gene targeting in estab-
lished brain tumors, we made use of the RCAS/tv-a system to
initiate brain tumors. The RCAS/tv-a system uses an avian retro-
viral vector, called RCAS, derived from avian leukosis virus (ALV,
subgroup A), and aNestin-tv-a (Ntv-a) transgenicmouse line that
expresses Tv-a (the receptor for ALV-A) under the control of the
Nestin gene promoter. This system makes it possible to transfer
and express exogenous genes in Nestin-expressing neural
progenitor cells and their progeny (Holland, 2001). With coinjec-
tion of RCAS viruses expressing AKT and platelet-derived
growth factor B (PDGFB), we were able to induce high-grade
brain tumors with full penetrance in Ntv-a mice (Figure 1A).
Approximately 60% of the tumors were multifocal glioblastoma
(GB) (Table S1 available online), which have classic histopatho-
logic features of human GB, like pseudopalisading-associated
necrosis and vascular proliferation (Figures 1B and 1C). These
tumors express the astrocyte marker glial filament acid protein
(GFAP) and the cell proliferation marker Ki67 (Figures 1D and
1E). All animals developed brain tumors within 3 months after
injection of PDGFB and AKT (Figure 1F). To determine the cell
of origin of brain tumors in this model, we injected the RCAS-
GFP producing DF-1 cells into the Ntv-a mice, which allow visu-
alization of infected cells with GFP signal. Three days after
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Targeting Brain Tumor Stem Cellsinjection, we found that most of GFP cells are located in the SVZ
area and all express GFAP and Nestin (Figures S1A and S1B),
suggesting the radial glia-like NSCs are the cells initially infected.
It is known that the SVZ NSCs mainly give rise to newborn neu-
rons in the olfactory bulb. One month after injection, we found
many GFP+ cells in the olfactory bulb (Figure S1C), which further
demonstrate that the NSCs are targeted by RCAS approach.
This is consistent with the working principle of this model that
only the Nestin-tv-a-expressing cells are infected by the RCAS
vectors (Holland et al., 1998). We also analyzed the tumor loca-
tion in many animals (Table S1). Most of the tumors are multi-
focal, but there is no strong correlation between tumor grade
and location. Nevertheless, SVZ is the most frequently associ-
ated region of tumor locations (Table S1), again suggesting the
stem cell origin of these tumors. This mousemodel allows induc-
tion of tumors without involving Cre/LoxP technology, thus the
Cre/LoxP system can be used for additional genetic manipula-
tions in mouse primary brain tumors. We then generated mouse
models with the following genotypes, Ntv-a;Tlx-GFP and Ntv-a;
Nestin-CreERT2;Tlxflox/flox. As we have shown in Tlx-GFP trans-
genic mice, in which the GFP expression is driven by a Tlx
bacterial artificial chromosome (BAC)-based promoter, that
NSCs are GFP+ (Feng et al., 2013), we are able to visualize the
Tlx expressing brain tumor cells via the GFP signal. Furthermore,
the Ntv-a;Nestin-CreERT2;Tlx flox/flox mice can be used to induce
Tlx inactivation in PDGFB/AKT-induced brain tumors, in a
tamoxifen (TMX)-dependent manner.
Tlx+ Cells in Mouse Brain Tumors Are Slow-Dividing
Cells
After induction of tumors in Tlx-GFP;Ntv-a mice, we observed
heterogeneous expression of GFP in mouse brain tumors (Fig-
ure 2A). To further characterize the Tlx-GFP tumor cells in vivo,
we performed additional immunohistochemistry (IHC) analysis,
and we found that the GFP+ cells were negative for Olig2 (Fig-
ure 2B), a common glioma marker and an oligodendrocyte
marker in normal brain tissues. We found that some of the
GFP+ cells were also positive for GFAP, which is a marker for
mature astrocyte and radial glia like NSCs in adult brain (Fig-
ure 2C). GFP+ cells were also negative for doublecortin (DCX),
a marker for immature neurons (Figure 2D). We found that a
commonly used marker for NSCs, NESTIN, is widely expressed
in the mouse tumors and that the Tlx-GFP+ cells are just a
subpopulation of NESTIN+ cells (Figure 2E). It has been sug-
gested that CSCs are slow-dividing cells that is one of the major
features of many tissue-specific stem cells (Li and Clevers,
2010). By costaining of GFP with the cell proliferation marker
Ki67 and another widely used stem cell marker, Sox2, we found
that most of the GFP cells were negative for Ki67 (Figure 2F).
Interestingly, the majority of the Sox2 cells were negative for
Tlx-GFP but positive for Ki67 (Figure 2F). We further quantified
the relative distribution of Tlx-GFP cells comparing with three
markers (Sox2, GFAP, NESTIN), the result indicates that Tlx-
GFP marks a unique population in primary brain tumors
(Figure 2G). Using additional cell proliferation markers like prolif-
erating cell nuclear antigen (PCNA) (Figure S2A) or MCM2 (Fig-
ure S2B) further confirmed that Tlx+ cells are largely quiescent
(Figure 2H). This result suggests that the Tlx-GFP+ tumor cells
are not fast-dividing cells in vivo, and it is known that most ofCthe Tlx-expressing cells in the SVZ are slowly dividing in vivo
(Liu et al., 2008). This could be further confirmed by bromodeox-
yuridine (BrdU) pulse labeling (2 hr) experiments, which showed
that a small population (6.3%) of the BrdU-incorporating cells
were positive for GFP and around 9.4% of the GFP+ cells incor-
porated BrdU (Figure 2I). This is consistent with the results
obtained by containing of Tlx-GFP with proliferation markers
(Figure 2H). BrdU label retention experiments have been used
to demonstrate the slow-dividing features of normal stem cells
(Bickenbach, 1981). We performed BrdU injections for 3 consec-
utive days and mice were analyzed 2 weeks after the last BrdU
injection, which allowed us to visualize the BrdU label-retaining
cells (LRC) in tumor tissues. We observed that most of the
BrdU label retaining cells (74.5%) are GFP+ (Figure 2J, arrows),
which strongly suggests that Tlx-GFP+ cells are the slow-
dividing cells in brain tumors. We also found that the Tlx-GFP+
BrdU LRC cells are positive for GFAP or NESTIN, but are nega-
tive for Sox2 (Figures S2C–S2E). The Tlx-GFP LRC cells are
Olig2+ and Sox2 (Figures S2F and S2G), suggesting these are
the fully differentiated tumor cells.
The neurosphere assay has been widely used for the determi-
nation of the existence of self-renewing cells in brain tissues
(Singec et al., 2006). Here, we found that when tumor cells are
placed into tumorsphere culture medium containing FGF2 and
EGF, the vast majority of tumorspheres are GFP+ (Figure 2K).
We isolated the Tlx-GFP+ and GFP cells via fluorescence-
activated cell sorting (FACS) from primary tumors, these two
populations were cultured in parallel using tumorsphere culture
conditions. We found that only the Tlx-GFP+ cells form tumor-
spheres and they can be passaged multiple times. The Tlx-
GFP cells cannot form tumorspheres efficiently and no spheres
can be further passaged (Figure 2L).
It is intriguing that many GFP+ cells are located in close prox-
imity to the vasculature as shown by staining of an endothelial
marker CD34 (Figure 2M), suggesting that the GFP+ cells are
located in a vascular niche. This is further supported by
measuring the average distance between GFP cells and CD34+
endothelial cells. The distance is significantly shorter than the
distance between Ki67+ and CD34+ cells (Figures 2M and 2N).
Although this is in line with a well-recognized feature of BTSCs,
the slow-dividing feature of the perivascular cells does not
support the notion that the vascular niche is supporting the
proliferative capacity of stem cells. These results suggest that
Tlx-GFP cells are the bona fide slow-dividing BTSCs in primary
brain tumors.
Xenotransplantation and Lineage Tracing Demonstrate
that Tlx-GFP Cells Are BTSCs
BTSCs were initially defined as cells that can initiate new tumors
when transplanted into immunocompromised mice (Singh et al.,
2004). To test whether there is a difference between Tlx-GFP+
and Tlx-GFP cells regarding their potential to initiate tumors
after transplantation, we performed the following serial trans-
plantation experiment. Tlx-GFP+ and Tlx-GFP cells were
isolated via FACS. A different number of cells (105, 104) were
injected intracranially into the brains of nude mice. Animals
were monitored with a 9.4 Tesla MRI device to determine tumor
frequency (Figure 3A). We found that the Tlx-GFP cells form
tumors very efficiently upon transplantation, and the tumorsell Stem Cell 15, 185–198, August 7, 2014 ª2014 Elsevier Inc. 187
Figure 2. Characterization of Tlx-GFP+ Cells in Primary Mouse Brain Tumors
(A) GFP staining of mouse tumors developed in Ntv-a;Tlx-GFP mouse brain. Note that there is only a subset of tumor cells that are positive for GFP. Scale bar
represents 20 mm.
(B–E) Brain tumor sections derived from Ntv-a;Tlx-GFP mouse brain were stained for: GFP (green), Olig2 (red) (B); GFP (green), GFAP (red) (C); GFP (green) DCX
(red)(D), and GFP (green), NESTIN (red)(E). Note that there is no colocalization betweenGFP, Olig2, and DCX. Only a subset of GFAP or NESTIN cells express Tlx-
GFP. Scale bars represent 20 mm.
(F) Staining of Ntv-a;Tlx-GFP brain tumor sections with GFP(green)/Ki67(blue)/Sox2(red) antibodies demonstrates that most of the Tlx-GFP cells are negative for
Ki67 and Sox2 staining. This suggests they are quiescent in vivo. Note that most of the Ki67+ cells express Sox2. Scale bars represent 50 mm.
(G and H) Quantification of relative distribution of Tlx-GFP+ cells comparing with different markers (G: Sox2, NESTIN, GFAP; H: Ki67, MCM2, and PCNA). Note
that none of these markers can exclusively label Tlx-GFP cells.
(I) BrdU labeling was performed to see the proliferation in tumor mice. BrdU injection to Ntv-a;Tlx-GFP tumor-bearing mice was performed 2 hr before sacrificing
themice. BrdU (red) andGFP (green) costaining of tumor sections were performed. Note that only a very small populations of GFP cells are BrdU+ (inset showing a
higher magnification of a BrdU and GFP double-positive cell). Scale bar represents 20 mm.
(J) Ntv-a;Tlx-GFP tumor mice received 3 days consecutive BrdU injections and the mice were sacrificed 3 weeks after the last injection. BrdU (red) and GFP
(green) costaining of tumor sections were performed. Note that the BrdU label-retaining cells are GFP+ (arrows). Inset: a higher magnification of a BrdU and GFP
double-positive cell. Scale bar represents 20 mm.
(legend continued on next page)
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pseudopalisading-associated necrosis and vascular prolifera-
tion (Figures 3A and 3D). The Tlx-GFP cells rarely form tumors
upon transplantation of 105 cells (Figure 3A). We also analyzed
the tumors initiated by Tlx-GFP+ cells. Although we only injected
Tlx-GFP-pure population, the heterogeneous expression pattern
of Tlx-GFP is reestablished in transplanted tumors and they are
still restricted in the slow-dividing subpopulation in primary
tumors shown by costaining with PCNA or NESTIN (Figures 3B
and 3C). This suggests the GFP+ cells are able to generate
GFP+ and GFP cells after transplantation. All animals devel-
oped tumors after injection of 104 Tlx-GFP+ cells, but no tumors
were observed with injection of the same amount of Tlx-GFP
cells (Figure 3D). Most importantly, the tumors initiated by Tlx-
GFP+ cells could be serially transplanted up to at least three
times during our analysis time (Figures 3E and 3F). The one tumor
initiated by the GFP population (1/7) can be further trans-
planted, but the histology analysis indicates that it is a rather
benign tumor without the histological features of GB (Figure 3G
and 3H). Most importantly, we did not observe Tlx-GFP expres-
sion in transplanted tumors from Tlx-GFP cells, indicating that
reacquiring Tlx-GFP expression is not a frequent event in vivo.
This result demonstrated that Tlx-GFP tumor cells can reestab-
lish a heterogeneous tumor upon transplantation. We also per-
formed a similar transplantation experiment using FACS-isolated
primary Tlx-GFP+ and Tlx-GFP cells. The results are consistent
with the experiment described above (Figure S3) suggesting that
Tlx-GFP+ cells are the cells that can serially transplant tumors.
The limitation of the xenotransplantation assay has been
raised recently (Magee et al., 2012). This prompts us to perform
the lineage tracing experiment to visualize the potential of Tlx+
tumor cells. As shown in Figure 3I, Tlx-GFP;Tlx-CreERT2;Ntva;
Confetti tumor-bearing mice were treated with TMX to induce
Cre-dependent recombination only in the Tlx-GFP cells because
Cre is controlled by the Tlx promoter. The confetti mice allow
random labeling of cells with one of four random colors upon
Cre activation (Snippert et al., 2010). In our model, the tracing
was initiated in established tumors, thus no retracing experiment
is needed, which is different from the lineage tracing experiment
in a colon adenoma model (Schepers et al., 2012). We also
showed above that Tlx-GFP cells in the tumor are the tumor cells
because they initiate tumors upon transplantation. No recombi-
nation was observed without TMX treatment. After low-dosage
TMX treatment, we can specifically induce spark-labeling only
in the single Tlx-GFP+ cells in side tumor (Figure 3J). In this
experiment, the confocal setting can detect all colors during
the image acquisition, also excluding clones with mixed colors.
Seven days after TMX injection (as shown in Figure 3K, repre-
sented by YFP+ clone), we found that most of the clones are
two to three cells and they are grouped together. Thirteen days(K) All tumorspheres derived from the Ntv-a;Tlx-GFP tumors are positive for Tlx-G
that around 94.7% of cells are GFP+ in this culture.
(L) Ntv-a;Tlx-GFP brain tumors were separated into GFP+ and GFP populations v
spheres formed by 100 cells were quantified. Note that spheres derived from GF
(M) Ntv-a;Tlx-GFP brain tumors costained with CD34 (red), Ki67(blue), and GFP (
CD34+ endothelial cells. Scale bar represents 50 mm.
(N) The average distance between Tlx-GFP cells and CD34+ cells is shorter than
See also Figure S2.
Cafter TMX injection, more cells were found but the cells started
to migrate away from each other. It is important to note the
glioblastoma is one of the most invasive solid tumors, and our
data also demonstrated that invasive feature of these cells.
Two months after TMX treatment, we started to see big clones
that had infiltrated into different places inside tumors (Figure 3K).
This experiment clearly demonstrates that a single Tlx+ tumor
cell can generate big clones of tumor cells over the long term.
These results, together with the transplantation assay, strongly
suggest that Tlx-GFP cells are BTSCs in vivo.
Recently, it was demonstrated that BTSCs are resistant to
temozolomide (TMZ) treatment (Chen et al., 2012), most likely
because of their slow-dividing feature as we described. To test
whether Tlx-GFP cells become activated after TMZ treatment,
we applied TMZ as described in Figure 3L and followed with
CidU long-term tracing to label the slow-dividing Tlx-GFP cells.
IdU was injected into tumor mice 2 hr before analysis. We found
that without TMZ treatment, Tlx-GFP/CidU cells did not incor-
porate IdU during the analysis period, but the TMZ-treated Tlx-
GFP/CidU cells became IdU+ indicating that they reentered the
cell-cycle after TMZ treatment (Figure 3K). This suggests that
these cells are the cell-of-origin of relapsed tumors after
chemotherapy.
Inducible Inactivation of Tlx in Brain Tumors Leads to
Prolonged Survival
The fact that Tlx is an essential transcription factor for self-
renewal of NSCs and for brain tumor initiation from NSCs, led
us to investigate whether inactivation of Tlx can serve as a
therapeutic strategy for treating GB. We generated the Ntv-a;
Nestin-CreERT2;Tlxflox/flox mice for such an experiment. The
Tlx-GFP population is also positive for NESTIN (Figure 2I), which
suggests that we are able to induce the knockout of Tlx in brain
tumors using Nestin-CreERT2 mice, in which a TMX-inducible
Cre recombinase is expressed under the Nestin promoter.
Based on the observation of the survival of PDGFB/AKT-injected
animals, we decided to induce Tlx mutation with TMX 10 days
before the tumor-bearing animals were expected to develop
tumor-related symptoms (i.e., 2.5 weeks after RCAS-PDGFB/
AKT injection). We confirmed that high-grade tumors were
already developed in those animals at the stage they underwent
TMX treatment (Figure 4A; N indicates necrosis, n = 5). Control
animals were Ntv-a;Tlxflox/flox mice, which received identical
treatment. We observed that the Tlx mutant tumor mice survived
significantly longer than the control mice (Figure 4B), suggesting
that targeting Tlx in brain tumors is beneficial for the survival of
tumor-bearing animals. To confirm whether Cre recombination
is efficient in mutant tumors, both RNA and protein were isolated
for Tlx expression analysis, and we could confirm that Tlx RNA
and protein levels were both significantly downregulated in theFP, suggesting that only the Tlx-GFP cells can form tumorspheres in vitro. Note
ia FACS before being subjected to tumorsphere culture experiment. Number of
P can not be further passaged. p < 0.05.
green). Note that most GFP cells are negative for Ki67 and are associated with
that between Ki67 cells and CD34+ cells. p < 0.05.
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Figure 3. Xenotransplantation and Lineage Tracing Demonstrate that Tlx-GFP Cells Are BTSCs
(A) Tlx-GFP+ or Tlx-GFP (105) cells were injected into the brain of nudemice. H&E staining indicated that Tlx-GFP+ initiated tumors with GB features, but most of
the mice injected with Tlx-GFP cells did not develop tumors. Inset: MRI image of transplant-initiated tumors.
(B andC) Tumors initiated by Tlx-GFP+ are heterogeneous. Costaining of Tlx-GFPwith PCNA demonstrates that Tlx-GFP+ cells remain to be slow-dividing (B) and
it is restricted to a subpopulation of NESTIN expressing cells as in primary tumors (C).
(D) Summary of the transplantation experiment. When injected with 105 cells, all Tlx-GFP+-injected animals develop tumors, and these tumors can be serially
transplanted at least for three rounds. The one tumor initiated by the Tlx-GFP cells can be further transplanted. *Only the animal developed tumor was used for
(legend continued on next page)
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and 4D). We found that the Tlx mutant tumors were smaller (Fig-
ure 4E). It is worth noting that most Tlx mutant animals still
showed neurological symptoms and brain tumors could still be
observed, although the Tlx mutant brain tumors were much
smaller and less infiltrative (Figure 4F). Furthermore, we per-
formed histological analyses of all tumors, and strikingly the
majority of the Tlx mutant tumors did not have features of GB
(e.g., pseudopalisading and vascular proliferation) (Figure 4G).
This could be further confirmed through neuropathological
assessment and grading according to the World Health Organi-
zation (WHO) classification of CNS neoplasias of all tumors by
a trained neuropathologist. Tlx mutant tumors had a lower grade
compared to the normal control tumors (Figure 4H). This result
also provides a possible link between BTSCs and GB
histopathology.
There are still tumor cells in the Tlx mutant mice. To assess the
potential of Tlx mutant tumor cells, we performed the trans-
plantation experiment after Tlx ablation. Primary tumors were
disassociated and 105 primary tumor cells were injected in all
the experiments. MRI was used to monitor tumors. The Tlx
wild-type (WT) tumor cells transplant tumors very efficiently as
shown in Figures 4I–4L. Histology analysis demonstrates that
Tlx mutant tumors are very small and benign (Figure 4M), and
we did not observe any histological features of GB. Importantly,
the WT tumors can be serially transplanted but the Tlx mutant
tumor failed to initiate any tumors for the secondary transplanta-
tion (Figures 4J, 4K, 4N, and 4O). These results strongly suggest
that Tlx is required for tumor propagation in the transplantation
assay.
These results suggest that death of animals in the Tlx mutant
group was driven by cells derived from BTSCs before TMX
treatment, which was sufficient to cause damage of normal brain
tissues and animal death as a consequence. To test this hypo-
thesis experimentally, we decided to inactivate Tlx by injecting
RCAS-Cre together with PDGFB and AKT to achieve an early
deletion of Tlx gene during tumor development. We found that
many animals did not get tumors in the Cre group compared to
the group injected with RCAS-GFP together with PDGFB and
AKT (Figure S4). This experiment suggests that early treatment
of tumor stem cells will greatly improve treatment outcome.
Tlx Inactivation Leads to Loss of Self-Renewing BTSCs
To analyze the cellular consequences in the primary tumor after
Tlx deletion, we analyzed the cell proliferation in the tumors after
the animals were sacrificed because of brain tumor-related
symptoms and found that there were significantly less Ki67-ex-secondary transplantation, six animals received cells from Tlx-GFP tumor and t
104 cells, only the Tlx-GFP+ cells initiated tumors.
(E–H) H&E staining of tumors from the serial transplantation experiment. Note that
(E and F), like necrosis (N), which was never observed from the Tlx-GFP-derive
(I–K) Lineage tracing of Tlx+ cells in primary tumors. (I) Experimental scheme. (J) TM
Tlx+ cells, RFP indicating cells being labeled by Cre recombination. (K) Represent
YFP after TMX treatment. Scale bars represent 20 mm if not indicated.
(L) Tlx-GFP tumor-bearing mice received TMZ treatment as described. CidU wer
performed in 1 day with 2 hr intervals. Three days later, animals were injectedwith
CidU(red), IdU(blue)n andGFP (green). Note that in the vehicle-treated brains, GFP
but in the TMZ-treated brains, GFP/CidU+ cells incorporate IdU indicate that the
See also Figure S3.
Cpressing cells in the Tlx mutant tumors. This suggests there
was a reduced proliferation upon Tlx deletion (Figure 5A). As
Tlx is only expressed by the slow-dividing cells in brain tumors,
we hypothesized that the decrease in Ki67+ cells in Tlx mutant
tumors was the consequence of Tlx inactivation in BTSCs. Inter-
estingly, when we analyzed tumors 5 days after TMX injection,
we found that the number of Ki67+ cells was not changed in
the Tlx mutant tumors. This suggests that loss of Tlx results in
a decreased generation of Ki67+ proliferating cells (Figure 5B).
To further investigate whether loss of Tlx leads to an impaired
function of BTSCs, we performed a tumorsphere assay, which
showed that Tlxmutant tumors generate significantly less tumor-
spheres (Figures 5C and 5D), and the mutant tumorspheres
could not be further passaged and expanded (Figure 5D). To
determine whether this is due to the loss of Tlx in BTSCs, we per-
formed the tumorsphere culture assay using cells derived from
the Ntv-a;Nestin-CreERT2;Tlxflox/flox tumors. Seventy-two hours
after adding 4-hydroxytamoxifen (4-OHT) to the tumorsphere
culture medium to induce Tlx deletion in vitro, we confirmed
that Tlx was successfully removed from the cells (Figure 5E).
We found that the Tlx mutant tumorspheres could not be
passaged as efficiently as Tlx+ tumor spheres (Figures 5E and
5F), suggesting that loss of Tlx in BTSCs leads to loss of self-
renewal. To investigate whether loss of Tlx leads to an altered
differentiation capacity of BTSCs, we established adherent
cell cultures from untreated Ntv-a;Nestin-CreERT2;Tlxflox/flox
tumors. After treatment with 4-OHT, the growth factors were
removed from the medium to induce the differentiation process.
We found a reduction of glial differentiation in Tlx mutant cells
shown by GFAP or Olig2 staining (Figures 5G and 5H), whereas
neuronal lineage differentiation was increased in Tlx mutant
BTSCs shown by DCX staining (Figure 5I). These results demon-
strated that loss of Tlx in primary brain tumors leads to loss of
self-renewal and induction of neuronal differentiation, which
may explain the survival effect of targeting Tlx in mouse gliomas.
Loss of Tlx in Brain Tumors Leads to the Induction of
Pathways Regulating Apoptosis, Senescence, and
Differentiation
To investigate the molecular pathways that are altered after Tlx
mutation in brain tumors, RNA was isolated from control and
mutant tumors and subjected to microarray analysis providing
insights into genome-wide expression changes after Tlx inacti-
vation. Interestingly, many pathways involved in cell-cycle regu-
lation, apoptosis, neural differentiation, and senescence were
significantly altered (Table S2). Quantitative RT-PCR (qRT-
PCR) analysis for some of the candidate genes confirmed thathree developed tumors. #All tumors are low grade tumors. When injected with
the Tlx-GFP+ secondary and tertiary tumors have histological features of a GB
d tumors (G and H).
X induction of single cell recombination in Tlx-GFP tumor cells. GFP indicating
ative picture of clone growth over time initiated by a Tlx+ stem cell labeled with
e injected into these mice 1 day after TMZ treatment, and three injections were
IdU 2 hr before sacrificing. Brain sections were stained using antibodies against
/CidU+ cells do not incorporate BrdU indicating they are slow-dividing (arrows),
y reenter cell-cycle (arrows).
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Figure 4. Genetic Inactivation of Tlx in BTSCs Leads to the Loss of Self-Renewing BTSCs and Prolonged Survival
(A) H&E staining demonstrates that malignant brain tumors were already developed at the time point of receiving TMX injection. N, necrosis.
(B) The Kaplan-Meier survival curve of mice receiving TMX. Note that inactivation of Tlx via TMX leads to a significant prolongation of animal survival. (p =
9.2E–10E).
(C and D) RNA and protein were extracted from tumors of animals that were sacrificed at the onset of neurological symptoms. qRT-PCR analysis (C) demon-
strating that Tlx is efficiently deleted upon TMX treatment.(n = 6, p < 0.0001), This can be confirmed by the western blot results indicating that Tlx protein is absent
in the mutant tumors. Data are represented as mean ± SD if not specified.
(E) Brains obtained from Tlx wild-type tumors and Tlx mutant tumors.
(F and G) H&E staining of brain tumors after Tlx inactivation, tumor region wasmarked with a dash line. Note that the Tlx mutant tumors are much smaller and lack
glioblastomas histological features like necrosis (N) associated with pseudopalisading and vascular proliferation (arrow). Scale bars represent 200 mm (F) and
50 mm (G).
(H) WHO classification of Tlx mutant and control brain tumors. Note that there are much less grade IV GBs in the Tlx mutant group.
(I) Tumor cells were isolated before TMX treatment and subjected to stem cell culture condition, 4-OTH was used for induction of Tlx mutation, and 105 cells of
control and Tlx mutant were collected and injected to the nude mice brains. MRI were used to determine tumor frequency. Note that WT tumors can be serially
transplanted, and Tlxmutant tumor cells can not initiate any tumors for the secondary transplantation experiment. *All Tlxmutant cell initiated tumors are local and
do not shown any invasive pattern under MRI.
(J–O) Histology of transplanted tumors from the experiment described in (I). Note that high grade tumors can be initiated with WT cells (J and K), which can be
clearly visualized with 9.4 teslaMRI, whereas the tumor initiated from the Tlxmutant population is very small (M, arrow) and can not be further transplanted (N). No
tumor can be seen with the MRI for the secondary transplantation (O, arrow indicates the injection site).
See also Figure S4.
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upregulated. For instance, CDKN2A, CDKN2B, and PML are all
upregulated in the Tlx mutant tumors (Figures 6A–6C), suggest-
ing a general inhibition of tumor growth and induction of cell-
cycle arrest and cell death after Tlx inactivation. Also, we
confirmed that factors that are important for neuronal differenti-
ation were induced in the Tlx mutant tumors as well, for example
SMACC1, Dlx2, and TGFbR1 (Figures 6D–6F). These results
suggest that loss of Tlx leads to the induction of cell death and
differentiation pathways, which is consistent with the phenotype192 Cell Stem Cell 15, 185–198, August 7, 2014 ª2014 Elsevier Inc.we observed in the mice brain tumors. Dlx2 and TGFbR1 have
been suggested as essential regulators for neuronal differentia-
tion (Brill et al., 2008; Shah et al., 1996), which explains in part
the increase of neuronal differentiation of Tlx mutant BTSCs (Fig-
ures 5G–5I).
The microarray data reflects general changes of genes in a
mixed population. To further determine which molecular
pathways were altered in BTSCs after Tlx deletion, we isolated
the BTSCs from Nestin-CreERT2;Tlxflox/flox;Ntva tumor mice
untreated with TMX. The cells are cultured under monolayer
Figure 5. Loss of Tlx in BTSCs Leads to the Loss of Self-Renewal and Induction of Neuronal Differentiation
(A) Ki67 staining of Tlxmutant and control brain tumors. Proliferation indexmeans percentage of Ki67+ cells in tumors (n = 4, p < 0.01). Scale bar represents 50 mm.
(B) Five days after TMX induction of Tlx mutation, brain tumors were analyzed for Ki67 staining. Note that no significant differences were observed between
normal tumors and Tlx mutant tumors. (n = 4, p = 0.238). Scale bar represents 50 mm.
(C and D) Fewer tumorspheres were derived from Tlx mutant tumors (C). Tumorspheres obtained from Tlx mutant tumors cannot be passaged in vitro whereas
control tumorspheres can be passaged and expanded (D). Scale bars represent 50 mm.
(E and F) Tumorsphere culture from the Ntv-a;Nestin-CreERT2;Tlxflox/flox tumors untreated with TMX. 4-OTH was added to the tumorspheres culture medium to
induce Tlx mutation in vitro. Western blot shows that Tlx can be efficiently removed after 72 hr of 4-OTH treatment (E). Much less tumorspheres were obtained
from Tlx mutant cells after the first passage (E), the Tlx mutant tumorspheres cannot be further passaged and expanded (F, p < 0.001 both in the first and second
passages). Scale bars represent 50 mm.
(G–I) 4-OTH was added to adherent culture of the Ntv-a;Nestin-CreERT2;Tlxflox/flox tumors. Growth factors were then removed to induce differentiation. Anti-
bodies against GFAP (G), Olig2 (H), and DCX (I) were used for staining of differentiated cells. Note that there are less GFAP and Olig2+ cells in the Tlx mutant
culture, but an increase of DCX+ cells was observed in the Tlx mutant culture. Scale bars represent 50 mm.
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allowed inactivation of Tlx in BTSCs (Figure 6G). We also
included two known Tlx target genes (PTEN and p21) that were
reported to be repressed by Tlx (Sun et al., 2007; Zhang et al.,
2006). RNA expression analysis shown in Figure 6G suggests
that as known Tlx target genes, only p21 (CDNK1A), but notCPTEN, is upregulated upon Tlx inactivation in BTSCs. PML,
TGFbR1, SMARCC1, and DCX are upregulated suggesting that
these genes are initially upregulated in Tlx mutant BTSCs,
although it is not known yet whether the expression of these
genes are repressed by Tlx protein directly, whereas CDKN2A
and CDKN2B are not altered in Tlx mutant BTSCs (data notell Stem Cell 15, 185–198, August 7, 2014 ª2014 Elsevier Inc. 193
Figure 6. Loss of Tlx in Brain Tumors Leads to Changes in Multiple Essential Pathways Regulating Apoptosis, Senescence, and Differenti-
ation
(A–F) qRT-PCR assay using RNA isolated from normal brain, control, and Tlx mutant tumors. Results show the induction of the expression of CDKN2A, CDKN2B,
PML, SMARCC1, Dlx2, and TGFbR1 in Tlx mutant tumors (n = 6 for each group, p < 0.05).
(legend continued on next page)
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Targeting Brain Tumor Stem Cellsshown), suggesting that the upregulation of these two genes
are secondary consequences upon Tlx deletion in primary
tumors. It is important to note that we have shown that Tlx over-
expression in NSCs does not lead to changes of CDKN2A/
CDKN2B expression (Liu et al., 2010), which is consistent with
the current results.
It is intriguing that we found factors like p21, CDKN2A,
CDKN2B, and PML are all upregulated in the Tlx mutant,
although not necessarily only in BTSCs. Additionally, we
confirmed the upregulation of CDKN2A (ARF/INK4A), CDKN2B
(INK4B), and PML in Tlx mutant tumors by IHC (Figures 6H–
6K), suggesting upregulation of these genes in many tumor cells.
These factors are known to be involved in the regulation of cell-
cycle arrest, apoptosis, and senescence (Gil and Peters, 2006;
Sharpless and DePinho, 2007). To investigate whether any of
these phenotypes is induced in the Tlx mutant tumors, we first
analyzed apoptosis in the Tlx mutant brain tumors. TUNEL assay
was performed, and we found that there was a significant
increase of TUNEL+ cells in the Tlx mutant tumors (Figure 6L),
suggesting that loss of Tlx also leads to an increase in apoptosis
of tumor cells. Furthermore, in order to detect whether there is a
senescence phenotype after Tlx inactivation, we performed
senescence-associated beta-gal (SA-b-Gal) staining on tumor
sections. However, we could not detect any cellular senescence
in situ (data not shown). One explanation could be that the cells
that underwent senescence had been already removed by
macrophages from the primary tumors (Kay, 1975). To further
investigate whether there was an induction of senescence, we
isolated BTSCs from Nestin-CreERT2;Tlxflox/flox;Ntv-a tumor
animals that have not been treated with TMX. We treated the
cells with 4-OHT for 72 hr as described above, 4 days after
removal of 4-OHT from the medium, the SA-b-Gal assay was
performed. We observed an increase of b-Gal+ cells in the Tlx
mutant culture (Figure 6M), indicating an induction of senes-
cence after inactivation of Tlx in BTSCs. The senescence pheno-
type is likely caused by activation of p21 in BTSCs. These results
suggest that the p21, INK4A/ARF, INK4B, and PML pathways
are induced upon removal of Tlx in BTSCs, which leads to pro-
longed survival of tumor-bearing mice.
Tlx Is Important for Self-Renewal of Human BTSCs
We have shown previously that Tlx is upregulated in human brain
tumors (Liu et al., 2010). Most importantly, by analyzing the
Cancer Genome Atlas (TCGA) data set (http://hgserver1.amc.
nl/cgi-bin/r2/main.cgi), we found that Tlx high expression corre-
lates with poor survival in human GB patients, indicating that Tlx
is a prognosis marker and a therapeutic target for human GB
(Figure 7A).
To investigate whether loss of Tlx in human BTSCs will lead to
similar phenotype as we observed in mice, we obtained three(G) 4-OHT was added to adherent cultures of the Ntv-a;Nestin-CreERT2;Tlx flox/flo
Tlx can be efficiently removed by 4-OHT treatment. Results show that p21, PML
(H–L) Mouse brain tumors were stained for INK4B (H), INK4A (I), ARF (J), and PML
represent 50 mm in (H–J) and 20 mm in (D).
(L) TUNEL assay demonstrated that there are more apoptotic cells in Tlx mutant
(M) 4-OHT was added to adherent cultures of the Ntv-a;Nestin-CreERT2;Tlx flox/fl
(SA-b-Gal) was performed. Note that there are more SA-b-Gal+ cells in Tlx muta
See also Table S2.
Cdifferent patient-derived human glioblastoma stem cells. Two
small hairpin RNAs (shRNAs) against the human Tlx gene were
used for knock down (KD) of Tlx in human BTSCs, as shown in
Figure 7B. Tlx expression is silenced by the two independent
shRNA constructs, using shRNA against luciferase as control.
We then analyzed the sphere formation ability of Tlx KD human
BTSC. Similar to the results in mouse BTSCs, we found that
Tlx inhibition leads to loss of sphere-forming ability and a
decrease of proliferation of human BTSCs (Figures 7C, 7D, and
S5), and no Tlx-KD cells can be passaged three times for further
analysis. We then analyzed genes that are changed in Tlx mutant
mouse cells. p21 and PML were found to be upregulated in Tlx
KD cells, which explains the sphere-forming results. We also
found that Tlx KD leads to upregulation of TGFbR1 and Dlx2,
suggesting an increase of neuronal differentiation, as we have
seen in the mouse mutant cells (Figure 7E). We did not observe
changes of CDKN2A, CDKN2B, SMARCC1, and PTEN (data
not shown). These results suggest that Tlx is important for the
regulation of human BTSCs.
Here, we demonstrate that Tlx is expressed in slow-dividing
BTSCs of primary brain tumors by using a mouse somatic brain
tumor model. Lineage tracing of single Tlx+ cells in vivo demon-
strate they are BTSCs. We also achieved BTSC-specific genetic
targeting of Tlx in established brain tumors and showed that Tlx
is essential for brain tumor maintenance and survival of tumor-
bearing mice (Figures 7H and 7I). These results strongly support
the CSCs hypothesis and provide direct evidence of improved
animal survival after targeting BTSC.
DISCUSSION
Cancer Stem Cells Are Suitable Therapeutic Targets
The CSCs hypothesis is under intensive debate. One major
reason is that markers used for CSCs isolation are not reproduc-
ible, which may reflect the genetic and phenotypic heterogeneity
of malignant cells or transient expression of these markers. The
scientific community faced similar problems when they started
to identify adult stem cells in different organs and tissues. The
controversies were later alleviated mostly by using animal
models, which allow genetic manipulation of particular cell types
and follow their behavior for a life-long time (Kretzschmar and
Watt, 2012). Recently, several studies were published, which
demonstrated the existence of CSC-like cells in different tumor
entities using different genetic tools (Chen et al., 2012; Driessens
et al., 2012; Schepers et al., 2012). These studies strongly sug-
gest the existence of a differentiation hierarchy in primary
tumors. Here, we demonstrated that in a mouse glioma model,
a subset of glioma cells expressing the functional NSC marker
Tlx, and these cells are slow-dividing in vivo. The Tlx-GFP cells
are the cells that can form long-term self-renewing spheresx tumors to induce Cre recombination. RNA was collected for qRT-PCR assay,
, TGFbR1, SMARCC1, and DCX are induced upon Tlx inactivation in BTSCs.
(K). All the four proteins were upregulated in the Tlx mutant tumors. Scale bars
brain tumors (n = 4, p < 0.01). Scale bar represents 50 mm.
ox tumors to induce Cre recombination, a senescence-associated b-gal assay
nt culture (n = 4, p < 0.01). Scale bar represents 50 mm.
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Figure 7. Tlx Is a Therapeutic Target in
Human BTSCs
(A) The Kaplan-Meier survival curve of GB patients
from the TCGA database. Note that patients with
higher Tlx expression have a worse survival rate
than patients with lower Tlx expression (p < 0.05).
(B) Knock-down (KD) of Tlx expression in human
BTSCs was achieved by using two independent
shRNAs against human Tlx (p < 0.05).
(C and D) KD of Tlx in human BTSCs (T269) leads
to loss of sphere forming ability and decrease of
cell proliferation measured by BrdU (red) assay.
(D) Arrow indicates GFP/BrdU double-positive
cells). BrdU was added to the medium for 3 hr
before analysis, GFP indicates the shRNA-
infected cells (p < 0.05 for passage 1 and pas-
sage 2).
(E) KD of Tlx leads to upregulation of p21, Dlx2,
PML, and TGFbR1 expression in human BTSCs
(p < 0.05).
(F and G) Graphic illustration of Tlx expression is
restricted to the slow-dividing BTSCs (F). Removal
of Tlx in the BTSCs leads to regression of brain
tumors (G) through induction of differentiation,
senescence, and apoptosis pathways.
See also Figure S5.
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that Tlx+ cells can generate large tumor clones over 2 months.
Most importantly, we showed that inactivation of Tlx in brain
tumors leads to a prolongation of survival of tumor-bearing
animals. This is, in part, due to the induction of several key
pathways, which are important for the regulation of senescence,
apoptosis, cell-cycle, and differentiation (Figures 7F and 7G).
This suggests that the tumor maintenance is dependent on the
BTSC population, and loss of this tumor-seeding population
will lead to regression of the tumor mass. This directly demon-
strates that BTSCs are important for tumor progression and
survival.
Nevertheless, it is noteworthy that the Tlx mutant tumors do
not disappear. There are several possible explanations of this
result. First, the gene targeting of Tlx in BTSCs was initiated in
Tlx expressing slow-dividing cells, and the proliferating cells
are not affected at the beginning of the targeting (Figure 5B).
These cells can still drive the tumor growth until they are
exhausted. This growth is causing neurological symptoms in
the Tlx mutant mice and this was further supported by the results
obtained by inactivating Tlx at early time point (Figure S4).196 Cell Stem Cell 15, 185–198, August 7, 2014 ª2014 Elsevier Inc.Second, there could be another Tlx-
independent BTSC population, which
can compensate the effect of Tlx loss,
although our serial transplantation exper-
iment showed that Tlx mutant tumor cells
cannot be serially transplanted. Third, it
could be possible that some Tlx+ cells
escaped TMX-induced Cre recombina-
tion and later contributed to tumor
growth. However, we did not observe
reappearance of Tlx for a long time after
the last TMX treatment, which doesnot support this hypothesis. Thus we would favor the first expla-
nation for this phenotype.
Role of Tlx in Normal and Cancer Stem Cells
It was known that Tlx is important for adult NSC maintenance in
the SVZ (Liu et al., 2008) and that overexpression of Tlx leads to
glioma initiation in mouse models when combined with p53
mutations (Liu et al., 2010). High expression of Tlx was found
in different types of tumors in the CNS, including astrocytoma,
ependymoma, and GB (Liu et al., 2010). Here, we directly
demonstrated that Tlx is also important for BTSCs maintenance.
These results suggest that Tlx is an essential regulator and
marker for stem cell features in BTSCs. It is interesting to see
that inactivation of Tlx in tumors leads to the induction of path-
ways involved in regulation of cell death, cell-cycle, and neuronal
differentiation. We observed that the Tlx target gene p21, which
is an essential factor mediating cell-cycle arrest and senescence
(Rowland and Peeper, 2006), is upregulated both in mouse and
human BTSCs upon removal of Tlx, suggesting this is a very
conserved pathway. To our knowledge, it has never been shown
that Tlx inhibits the INK4A/ARF pathway in normal NSCs, and we
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Targeting Brain Tumor Stem Cellsdid not see changes of INK4A/ARF expression in Tlx over-
expressing NSCs (Liu et al., 2010). This suggests that the upre-
gulation of INK4A/ARF upon inactivation of Tlx is tumor-specific.
It was shown that Tlx represses expression of PTEN, which are
thought to be essential for maintaining NSC proliferation (Zhang
et al., 2006). Here, we did not observe PTEN upregulation in the
mutant tumors from themicroarray analysis. One possible expla-
nation is that PTEN is silenced or mutated in the AKT+PDGFB-
induced high-grade mouse GBs by other mechanisms, which
occurs often in human GB patients as well (Furnari et al., 2007).
Taken together, we demonstrated here that Tlx is an essential
indicator and regulator of BTSCs. The mouse models we gener-
ated provide additional approaches for therapeutic target valida-
tion. We also demonstrated that Tlx is a prognosis marker for
poor survival of human GB patients, which together with our
mouse data suggest that Tlx is a promising therapeutic target
for brain tumors. Another advantage of targeting Tlx in brain
tumor is that Tlx expression is restricted to the CNS system
(Monaghan et al., 1995) and hence an inhibitor that is specifically
blocking Tlx activity will have few side effects. As many other
nuclear receptors, Tlx is very likely a druggable protein.
EXPERIMENTAL PROCEDURES
Animal Experiments
Mice were housed according to international standard conditions and all
animal experiments complied with local and international guidelines for the
use of experimental animals. The Ntv-a mouse was kindly provided by Eric
Holland. Tlx flox/flox animals was generated as described (Belz et al., 2007).
The Nestin-CreERT2 animal was generated as described elsewhere and has
been successfully used to target both SVZ and SGZ NSCs via tamoxifen injec-
tion (Corsini et al., 2009). Tlx-GFP reporter animal was obtained from the
GENSAT project (Gong et al., 2003). Confetti mice were from Jackson Labora-
tory. Tamoxifen (Sigma) was dissolved in sunflower seed oil (Sigma) with 10%
EtOHabs to prepare a 10 mg ml
1 solution. Intraperitoneal injections were per-
formed with 1 mg/day for 10 days. BrdU, CidU, or IdU (Sigma) were dissolved
in sterile 0.9% saline to prepare a 15 mgml1 solution, and mice were injected
intraperitoneally with 300 mg kg1 2 hr before sacrifice or with 100 mg kg1/
day for 3 days as described in this article. TMZ (Sigma) was dissolved in
DMSO and freshly diluted in 0.9% saline (5 mg/ml) and injected intraperitone-
ally with 100 mg kg1/day for 5 days.
RNA Isolation, RT-PCR, and Microarray
RNA from cultured NSCs and dissected mouse tumors and normal brain
tissues (mixture of tissues from olfactory bulb, cortex, striatum, hippocampus,
and hypothalamus) were isolated with RNeasy Mini Kit (QIAGEN) and tran-
scribed into cDNA using random primers (dN6, Roche). cDNA were quantified
with RT-PCR using TaqMan gene expression assays (Applied Biosystems).
The levels of four housekeeping genes including ActB, GAPDH, HPRT, and
PPIA were averaged and used for normalization. For the microarray experi-
ment, the quality of total RNA was checked by gel analysis using the total
RNA Nano chip assay on an Agilent 2100 Bioanalyzer (Agilent Technologies
GmbH). Only samples with RNA index values >7 were selected for expression
profiling. The analysis is done with R on the GeneView data produced by the
scanner.
Cell Culture
Mouse brain tumors were dissected and then digested with Accutase (Sigma-
Aldrich). Dissociated cells were grown to neurospheres in DMEM/F12 medium
containing 20 ng ml1 EGF (Sigma-Aldrich), 10 ng ml1 FGF2 (Sigma-Aldrich),
B27 (GIBCO), and ITSS (Roche). To establishmonolayer culture, neurospheres
were dissociated with Accutase (Sigma-Aldrich) and were seeded on laminin
(Roche) and poly-L-lysine (Sigma-Aldrich)-coated cell culture plates. For
the differentiation of NSCs, NSCs were dissociated with Accutase, andC2.5 3 104 cells were seeded on laminin and poly-L-lysine-coated coverslips
in one well of a 24-well plate. Cells were cultured for 14 days in NSCs medium
without EGF and with 5 ng ml1 FGF2. After 14 days, cells were collected for
analysis. Medium was renewed every 3 days for the whole procedure. For
in vitro CreERT2 induction, 4-hydroxytamoxifen (4-OHT, H7904; Sigma) was
dissolved in ethanol at a final stock concentration of 10 mM and kept in
single-use aliquots in the dark at –20C and added freshly to the medium.
To induce Cre activity in CreERT2-expressing BTSCs, medium was replaced
with the same medium but containing 5 M 4-OHT for 72 hr, then the medium
was again replaced with fresh medium without 4-OH for 4 days.
Immunohistochemistry and Western Blot
Mice were perfused with 4%paraformaldehyde, and the brains were postfixed
overnight at 4C. Vibratome sections (50 mm) or 5mm paraffin sections were
blocked in 5% normal swine serum in PBST (PBS + 0.2%, Triton X-100) and
incubated overnight at 4C with the primary antibody. The apoptosis assay
was performed by using the ApopTag Plus Peroxidase In Situ Apoptosis Kit
(Chemicon). The senescence analysis was carried out by using the Senes-
cence b-Galactosidase Staining Kit (Cell Signaling). Fluorescent images
were captured using a confocal laser-scanning microscope (LSM700, Zeiss).
Statistically significant results were followed up with Student’s t tests. For
western blot, protein extracts cultured brain tumor stem cells were subjected
to electrophoresis and transferred onto a PVDF membrane for immunoblot
analysis. The following antibodies were used: Tlx (1:500, rabbit), beta tubulin
(1:1,000; Cell Signaling).
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